MLYS vs. BHC, INDV, GPCR, DCPH, JANX, AMRX, GMTX, AMPH, VERA, and RCKT
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Bausch Health Companies (BHC), Indivior (INDV), Structure Therapeutics (GPCR), Deciphera Pharmaceuticals (DCPH), Janux Therapeutics (JANX), Amneal Pharmaceuticals (AMRX), Gemini Therapeutics (GMTX), Amphastar Pharmaceuticals (AMPH), Vera Therapeutics (VERA), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical preparations" industry.
Bausch Health Companies (NYSE:BHC) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, community ranking, profitability, analyst recommendations, valuation and dividends.
Bausch Health Companies received 341 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 61.90% of users gave Bausch Health Companies an outperform vote.
Mineralys Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
Mineralys Therapeutics has a net margin of 0.00% compared to Mineralys Therapeutics' net margin of -5.07%. Bausch Health Companies' return on equity of -32.48% beat Mineralys Therapeutics' return on equity.
78.7% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 8.1% of Bausch Health Companies shares are owned by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Bausch Health Companies has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.
Bausch Health Companies currently has a consensus target price of $11.33, suggesting a potential upside of 76.26%. Mineralys Therapeutics has a consensus target price of $33.50, suggesting a potential upside of 174.59%. Given Bausch Health Companies' stronger consensus rating and higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Bausch Health Companies.
In the previous week, Mineralys Therapeutics had 9 more articles in the media than Bausch Health Companies. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 2 mentions for Bausch Health Companies. Bausch Health Companies' average media sentiment score of 0.19 beat Mineralys Therapeutics' score of 0.05 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.
Summary
Mineralys Therapeutics beats Bausch Health Companies on 12 of the 17 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mineralys Therapeutics Competitors List
Related Companies and Tools
